Chemours Company (The) (NYSE:CC) SVP David C. Shelton sold 19,000 shares of the stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $53.68, for a total transaction of $1,019,920.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
David C. Shelton also recently made the following trade(s):
- On Thursday, August 31st, David C. Shelton sold 13,337 shares of Chemours Company (The) stock. The shares were sold at an average price of $48.48, for a total transaction of $646,577.76.
Shares of Chemours Company (NYSE:CC) opened at 54.67 on Friday. The firm has a market capitalization of $10.10 billion, a P/E ratio of 35.78 and a beta of 3.59. Chemours Company has a 12 month low of $14.41 and a 12 month high of $54.83. The company has a 50 day moving average of $51.45 and a 200-day moving average of $51.45.
Chemours Company (The) (NYSE:CC) last posted its quarterly earnings data on Wednesday, August 2nd. The specialty chemicals company reported $0.87 EPS for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.02. The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.49 billion. Chemours Company (The) had a return on equity of 122.97% and a net margin of 4.96%. The firm’s quarterly revenue was up 14.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.27 earnings per share. Analysts predict that Chemours Company will post $3.51 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Thursday, August 17th were paid a $0.03 dividend. This represents a $0.12 dividend on an annualized basis and a dividend yield of 0.22%. The ex-dividend date was Tuesday, August 15th. Chemours Company (The)’s dividend payout ratio is currently 8.11%.
COPYRIGHT VIOLATION WARNING: “Chemours Company (The) (CC) SVP Sells $1,019,920.00 in Stock” was reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://transcriptdaily.com/2017/10/08/chemours-company-the-cc-svp-sells-1019920-00-in-stock.html.
Institutional investors have recently bought and sold shares of the stock. Los Angeles Capital Management & Equity Research Inc. acquired a new position in Chemours Company (The) in the first quarter valued at approximately $450,000. Stifel Financial Corp lifted its stake in Chemours Company (The) by 6.3% in the first quarter. Stifel Financial Corp now owns 19,401 shares of the specialty chemicals company’s stock valued at $749,000 after buying an additional 1,146 shares during the period. Cipher Capital LP acquired a new position in Chemours Company (The) in the first quarter valued at approximately $320,000. Victory Capital Management Inc. acquired a new position in Chemours Company (The) in the first quarter valued at approximately $6,461,000. Finally, Schroder Investment Management Group acquired a new position in Chemours Company (The) in the first quarter valued at approximately $156,000. 72.90% of the stock is currently owned by institutional investors.
CC has been the topic of a number of analyst reports. BidaskClub downgraded shares of Chemours Company (The) from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Jefferies Group LLC reiterated a “buy” rating and issued a $48.00 price target on shares of Chemours Company (The) in a research report on Friday, June 16th. Citigroup Inc. upgraded shares of Chemours Company (The) from a “neutral” rating to a “buy” rating and increased their price target for the company from $43.00 to $45.00 in a research report on Wednesday, July 5th. Zacks Investment Research upgraded shares of Chemours Company (The) from a “hold” rating to a “strong-buy” rating and set a $51.00 price target on the stock in a research report on Friday, July 14th. Finally, Argus reiterated a “buy” rating and issued a $55.00 price target (up from $50.00) on shares of Chemours Company (The) in a research report on Thursday, August 10th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $52.75.
Chemours Company (The) Company Profile
The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.
Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.